Compare FCBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | OMER |
|---|---|---|
| Founded | 1874 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.5M | 788.4M |
| IPO Year | 1996 | 2008 |
| Metric | FCBC | OMER |
|---|---|---|
| Price | $41.00 | $10.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 72.0K | ★ 703.2K |
| Earning Date | 04-21-2026 | 03-12-2026 |
| Dividend Yield | ★ 5.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $12.28 | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | $15.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.21 | $2.95 |
| 52 Week High | $42.15 | $17.65 |
| Indicator | FCBC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 38.91 |
| Support Level | $38.60 | $10.55 |
| Resistance Level | $41.56 | $11.93 |
| Average True Range (ATR) | 1.08 | 0.47 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 85.28 | 9.71 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.